U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18N6O5S3
Molecular Weight 506.578
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CEFDITOREN

SMILES

[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(O)=O

InChI

InChIKey=KMIPKYQIOVAHOP-YLGJWRNMSA-N
InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H18N6O5S3
Molecular Weight 506.578
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 2
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/dosage/cefditoren.html http://www.rxlist.com/spectracef-drug.htm http://www.wikidoc.org/index.php/Cefditoren

Cefditoren pivoxil is a semi-synthetic cephalosporin antibiotic for oral administration. It is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, infection of skin and/or subcutaneous tissue, and pharyngitis/tonsillitis. Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Common adverse reactions include diarrhea, nausea and candida vaginitis. Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides or co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal. Co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Target ID: Q8XJ01
Gene ID: 990276.0
Gene Symbol: pbpA
Target Organism: Clostridium perfringens (strain 13 / Type A)
Target ID: P59676
Gene ID: 934744.0
Gene Symbol: pbpX
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
SPECTRACEF

Approved Use

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

2001
Curative
SPECTRACEF

Approved Use

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

2001
Curative
SPECTRACEF

Approved Use

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

2001
Curative
SPECTRACEF

Approved Use

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

2001
Curative
SPECTRACEF

Approved Use

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.8 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDITOREN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDITOREN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
12%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDITOREN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day steady, oral
Studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
healthy, 18-30 years
n = 8
Health Status: healthy
Age Group: 18-30 years
Sex: M
Population Size: 8
Sources:
Disc. AE: Gastrointestinal disturbance...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disturbance (1 patient)
Sources:
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, adult
n = 2150
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2150
Sources:
Disc. AE: Gastrointestinal disturbance, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disturbance (2%)
Diarrhoea (0.7%)
Sources:
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, adult
n = 2149
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2149
Sources:
Disc. AE: Gastrointestinal disturbance, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disturbance (3%)
Diarrhoea (1.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disturbance 1 patient
Disc. AE
400 mg 3 times / day steady, oral
Studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
healthy, 18-30 years
n = 8
Health Status: healthy
Age Group: 18-30 years
Sex: M
Population Size: 8
Sources:
Diarrhoea 0.7%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, adult
n = 2150
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2150
Sources:
Gastrointestinal disturbance 2%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, adult
n = 2150
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2150
Sources:
Diarrhoea 1.4%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, adult
n = 2149
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2149
Sources:
Gastrointestinal disturbance 3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, adult
n = 2149
Health Status: unhealthy
Condition: chronic bronchitis
Age Group: adult
Sex: unknown
Population Size: 2149
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Acute bacterial exacerbation of chronic bronchitis: 400 mg twice a day for 10 days. Community-acquired pneumonia: 400 mg twice a day for 14 days Tonsillitis/Pharyngitis and Uncomplicated Skin or Soft Tissue Infection: 200 mg twice a day for 10 days
Route of Administration: Oral
The level of cefditoren activity against S. pneumoniae (MIC(90,) 0.5 microg/mL) was superior to all marketed oral cephalosporins and at least equal to amoxicillin +/- clavulanate. H. influenzae (MIC(90,) 0.016-0.03 microg/mL) and M. catarrhalis (MIC(90,) 0.06-0.5 microg/mL) were also very susceptible to cefditoren. cefditoren was active against oxacillin-susceptible staphylococci (MIC(90,) < or = 1 microg/mL) at a level comparable to cefuroxime axetil, cefaclor or cefprozil.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:30:29 GMT 2023
Record UNII
81QS09V3YW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFDITOREN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CEFDITOREN [MI]
Common Name English
CEFDITOREN [VANDF]
Common Name English
Cefditoren [WHO-DD]
Common Name English
cefditoren [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
LIVERTOX 162
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
WHO-ATC J01DD16
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
WHO-VATC QJ01DD16
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
NDF-RT N0000175488
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
Code System Code Type Description
SMS_ID
100000081797
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
EVMPD
SUB07387MIG
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
INN
6919
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID501328012
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
CHEBI
59343
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
FDA UNII
81QS09V3YW
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
DAILYMED
81QS09V3YW
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL454446
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
LACTMED
Cefditoren
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
MERCK INDEX
m3192
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
CEFDITOREN
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
RXCUI
83682
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY RxNorm
DRUG BANK
DB01066
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
CAS
104145-95-1
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
PUBCHEM
9870843
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
MESH
C073460
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
NCI_THESAURUS
C72625
Created by admin on Fri Dec 15 16:30:30 GMT 2023 , Edited by admin on Fri Dec 15 16:30:30 GMT 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

FASTED CONDITION

Volume of Distribution PHARMACOKINETIC